ArticleJournal of the American Association for Laboratory Animal Science : JAALAS2025
Pharmacokinetics of a Transdermal Buprenorphine Topical Solution in the Cynomolgus Macaque (Macaca fascicularis).
Article in Journal of the American Association for Laboratory Animal Science : JAALAS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pain management is an expansive and ever-evolving component of managing nonhuman primates in the research setting. Opioids are a commonly used analgesic medication and are available in a variety of formulations. A novel, long-acting transdermal buprenorphine topical solution was recently approved for use in cats to provide up to 4 days of postoperative analgesia. The purpose of this study was to evaluate the pharmacokinetic profile of this transdermal formulation in cynomolgus macaques. Five male cynomolgus macaques were used in a 2-formulation crossover study to compare the pharmacokinetics of a single transdermal dose (20 mg) to a single intravenous dose of buprenorphine HCl (0.01 mg/kg). Plasma buprenorphine levels were measured for animals receiving transdermal buprenorphine topical solution at time points 0 (baseline), 1, 3, 6, 12, 24, 36, 48, 72, 96, and 120 hours postdosing. Plasma buprenorphine levels were measured for animals receiving intravenous buprenorphine at time points 0 (baseline), 2, 5, 10, 25, 45, and 60 minutes and at 3, 6, 12, and 24 hours postdosing. Animals weighing 3.55-6.2 kg reached therapeutic plasma levels, as hypothesized in the literature (0.1 ng/mL), within 1 hour of administration and maintained therapeutic levels for at least 72 hours. This study demonstrates that this novel transdermal buprenorphine topical solution can offer a refinement in pain management of nonhuman primates through a less invasive route of administration with an extended duration of action.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.